Catch up on the top stories in optometry during the week of June 9-June 13.

This new QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC; Qlaris) is in development for the treatment of primary open angle glaucoma, ocular hypertension, and normal tension glaucoma for patients whom optimal intraocular pressure control may remain “unachievable” due to needing to lower episcleral venous pressure.

Anthem will also be required to conduct quarterly self-audits beginning in July of this year in order to document the correction of the issues stated in the report.

Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.

The generic formulation references Pred Forte, which is trademarked by Allergan.

The report highlights clinical successes, innovation, research, and patient outcomes.

The Vision Lab Choice Act of 2025, S 1716 was introduced to the US Senate floor on May 12.

Incorporating peripheral OCTs into your practice provides valuable insights which may alter your clinical diagnosis.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

Bryce St Clair, OD, MPH, authors the June edition of the Cultural Responsiveness Blog, and urges doctors to consider cultural and socioeconomic backgrounds when caring for patients.

The ophthalmology platform Optegra operates more than 70 eye hospitals and diagnostic facilities in 5 European markets.

The study was an outgrowth of the phase 1 and 2 Ocular Hypertension Treatment Study (OHTS).

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

The device was developed by Curators’ Distinguished Teaching Professor Carl Bassi and research collaborators Michael Howe and Wayne Garver of the University of Missouri – St Louis.

Catch up on the top stories in optometry during the week of June 2-June 6.

Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.

At the 2025 ASCRS meeting, Mitch Shultz, MD, presented compelling new findings from a 12-week clinical trial investigating the impact of lotilaner 0.25% ophthalmic solution on meibomian gland function.

The 0.1 mg/mL atropine eye drop for paediatric myopia is licensed from Sydnexis, Inc.

An official approval by the FDA in the United States can boost adoption rate of atropine and antimyopia glasses, which will change the landscape of myopia management.